ORMP
Oramed Pharmaceuticals Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-26
Figures on this page computed 2026-11-08 12:40 UTC
Last close
4.13USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-26
2.5xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-10
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
-457.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Margins is the furthest below its sector's middle: 0.06 against 0.41 on the market's range.
- Growth-5.9%62 of 100, above its sector
- Returns on capital32.1%96 of 100, above its sector
- Margins0.7%6 of 100, below its sector
- Price2.5x58 of 100, above its sector
- Safety6.9874 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-03-26
- Sales0.91x
Its own average over 9 years, 2.2M.
- Profit-9.21x
Its own average over 10 years, -7.0M.
- Free cash flow0.77x
Its own average over 10 years, -11.9M.
- Debtn/a
Its own average over 6 years, 15.3M.
- Price0.74x
Its own average over 11 years, 6. Market data, 2026-11-04
Profit is furthest from its own average, at -9.21 times.
Sales is 0.91 times its own 9-year average; Profit is -9.21 times its own 10-year average; Free cash flow is 0.77 times its own 10-year average; Price is 0.74 times its own 11-year average.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-26
Sales against its own 9-year average0.91
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
Profit against its own 10-year average-9.21
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
Free cash flow against its own 10-year average0.77
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
Debt against its own 6-year averagen/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-034835
- Reported in
- USD
Price against its own 11-year average0.74Market data, 2026-11-04
- Source
- market
- Taken on
- 2026-11-04
- Reported in
- USD